Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03586414 · ClinicalTrials.gov registry record · NA

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

A NA study of Diastolic Dysfunction, sponsored by University of Colorado, Denver.

Active
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT03586414 is a NA study of Diastolic Dysfunction that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 31 participants, below the 583-participant average among 4 other Diastolic Dysfunction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03586414, a NA study of Diastolic Dysfunction, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT MITOQUINOL MESYLATE then placebo
  • DIETARY_SUPPLEMENT Placebo, then MITOQUINOL MESYLATE

Study Locations (1)

Colorado

  • University of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2021-08-01
Est. Completion 2030-08
Phase NA

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT03586414

The ClinicalTrials.gov registry entry for NCT03586414 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 583-participant average among 4 other Diastolic Dysfunction trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diastolic Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which MITOQUINOL MESYLATE then placebo is the first listed.

NCT03586414 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT03586414 about?

NCT03586414 is a clinical study titled "MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women". In this pilot study, the investigators will determine whether supplementation with a mitochondrial-targeted antioxidant (Mitoquinone (MitoQ)) improves mitochondrial function, left ventricular diastolic and vascular function.

What is the current status of trial NCT03586414?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2021-08-01. Estimated completion is 2030-08.

What conditions does trial NCT03586414 study?

This clinical trial studies the following conditions: Diastolic Dysfunction.

What interventions are being tested in trial NCT03586414?

The interventions under investigation include: MITOQUINOL MESYLATE then placebo (DIETARY_SUPPLEMENT), Placebo, then MITOQUINOL MESYLATE (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03586414?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03586414 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diastolic Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.